|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Protein C Activity
Test CodeQ1777
Preferred Specimen
1 mL frozen platelet-poor plasma collected in 3.2% sodium citrate (light blue-top) tube
Minimum Volume
0.5 mL (if single test)
Instructions
Please submit a separate, frozen vial for each special
coagulation assay ordered.
coagulation assay ordered.
Transport Container
Plastic vial
Transport Temperature
Frozen
Specimen Stability
Room temperature: Unacceptable
Refrigerated: Unacceptable
Frozen: 14 days
Refrigerated: Unacceptable
Frozen: 14 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Room Temperature or Refrigerated
Methodology
Clotting Assay
Setup Schedule
Set up: Tues-Sat; Report available: 1-4 days
Limitations
Expected impact by therapeutic levels (potential interference depends upon drug concentration): Warfarin: decrease; Heparin (UFH or LMWH): UFH-no effect, LMWH-may falsely increase at higher levels; Dabigatran or Argatroban (Thrombin Inhibitors): may falsely increase; Rivaroxaban or Apixaban (Factor Xa Inhibitors): may falsely increase.
Clinical Significance
Protein C (PC) deficiency may be congenital or acquired and is associated with venous thrombosis. Acquired PC deficiency may occur with vitamin K antagonists/deficiency, liver disease, malignancy, consumptive DIC, surgery, trauma, and hepatic immaturity of the newborn.
Anticoagulant interference: Expected impact by therapeutic levels (potential interference depends upon drug concentration): Vitamin K antagonists (eg warfarin): decrease; Heparin (UFH or LMWH): no effect to falsely increased activity levels at higher levels; Dabigatran or Argatroban (Thrombin Inhibitors): may falsely increase activity; Rivaroxaban, Apixaban, Edoxaban (Factor Xa Inhibitors): may falsely increase activity.
Anticoagulant interference: Expected impact by therapeutic levels (potential interference depends upon drug concentration): Vitamin K antagonists (eg warfarin): decrease; Heparin (UFH or LMWH): no effect to falsely increased activity levels at higher levels; Dabigatran or Argatroban (Thrombin Inhibitors): may falsely increase activity; Rivaroxaban, Apixaban, Edoxaban (Factor Xa Inhibitors): may falsely increase activity.
